NCT03711058: A reported trial by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03711058 |
|---|---|
| Title | A Phase I/II Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 17, 2019 |
| Completion date | June 14, 2022 |
| Required reporting date | June 14, 2023, midnight |
| Actual reporting date | May 18, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |